Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851068 | 0.86 | FFAR1 (0.42) | GPR84 | |
| SCHEMBL22819103 | 0.85 | NR1I2 (0.38) | CSNK1EKCNH2ALDH1A1GAAGPR84 | |
| SCHEMBL21101056 | 0.85 | NR1I2 (0.38) | CSNK1EKCNH2ALDH1A1GAAGPR84 | |
| SCHEMBL25866564 | 0.85 | NR1I2 (0.38) | CSNK1EKCNH2ALDH1A1GAAGPR84 | |
| SCHEMBL20372779 | 0.83 | NR1I2 (0.37) | CSNK1EKCNH2ALDH1A1GAAGPR84 | |
| SCHEMBL19198110 | 0.83 | NR1I2 (0.37) | CSNK1EKCNH2ALDH1A1GAAGPR84 | |
| SCHEMBL20098207 | 0.83 | NR1I2 (0.37) | CSNK1EKCNH2ALDH1A1GAAGPR84 | |
| SCHEMBL5694337 | 0.83 | CSNK1E (0.38) | CSNK1ECNR2ALDH1A1GAAGPR84 | |
| SCHEMBL4178697 | 0.81 | NR1I2 (0.40) | CSNK1ECNR2GAAGPR84 | |
| SCHEMBL22794936 | 0.81 | GPR84 (0.37) | CSNK1EMEN1KMT2ANPSR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306380-B1 | NOVEL EXPANDED PORPHYRINS AND PROCESS FOR THE SYNTHESIS THEREOF | JAPAN SCIENCE & TECH AGENCY (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-6822092-B2 | LARGER CYCLIC NITROGEN-NETWORK, RED-SHIFTED ABSORPTION BANDS, MORE FLEXIBLE CONFORMATION OF THE MACROCYCLES, AND COORDINATION ABILITY OF MORE THAN TWO METAL IONS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20030162963-A1 | Novel expanded porphyrins and process for the synthesis thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1306380-A1 | NOVEL EXPANDED PORPHYRINS AND PROCESS FOR THE SYNTHESIS THEREOF | Japan Science and Technology Corporation (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162963-A1 | Novel expanded porphyrins and process for the synthesis thereof | AAAS, PAM, AHR | CSNK1E 3307/4885CNR2 1817/4885MEN1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.